Abstract
The need for Group IIA secretory phospholipase A2 (sPLA2-IIA) inhibitors in inflammatory ocular disease treatment
Highlights
The highly cationic nature of secretory phospholipase A2 (PLA2) (sPLA2)-IIA allows the enzyme to bind and hydrolyze an anionic phospholipid on the cell membrane, especially when damaged and stressed, causing the release of lysophospholipid and free fatty acid
All phospholipase A2 (PLA2) enzymes are capable of hydrolyzing the center ester bond of a natural phospholipid substrate, giving lysophospholipid and free fatty acids, including arachidonic acid [1]
While new groups of PLA2 such as adipose-specific PLA2 (AdPLA2) have been identified, most research has focused on the five main groups: secretory PLA2, pancreatic or cytosolic PLA2, Ca2+ independent PLA2, platelet-activating factor (PAF) acetylhydrolase (PAF-AH), and lysosomal PLA2 [5]
Summary
The need for Group IIA secretory phospholipase A2 (sPLA2-IIA) inhibitors in inflammatory ocular disease treatment. Michael X Liu, Chao LV2, Jennifer S Feng, Penny A Asbell and Yi Wei1 1Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY 10029 2Yantaishan Hospital, Yantai, Shandong Province, China 264001
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
